Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

More growth potential is possible as the company pointed to positive data posted for adjuvant use of Libtayo in patients with cutaneous squamous cell carcinoma (CSCC). With that result ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The EC approved Libtayo – a fully human monoclonal ... (SCC), advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC), and advanced non-small cell lung cancer ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... 78% of patients had squamous cell carcinoma (SCC) and 22% had ...

Opens in a new tab or window SAN FRANCISCO -- A combination of cemiplimab (Libtayo ... for locally advanced or metastatic cutaneous squamous cell carcinoma. EPIC-A included 29 patients who ...